跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 19,933 条关于
“VMAT2 inhibitor”
全部
19,933
临床试验
9,793
药物
4,062
机构
20
资讯
6,058
去年
Neurocrine Launches Phase 1 Trial of Novel VMAT2 Inhibitor for Neurological Disorders
去年
Serina Therapeutics Advances Once-Weekly Injectable VMAT2 Inhibitor for Tardive Dyskinesia Treatment
5年前
Luye Pharma's Next-Generation VMAT2 Inhibitor LY03015 to Begin Clinical Trials in the U.S.
8个月前
INGREZZA Demonstrates Nearly Two-Fold Higher VMAT2 Target Occupancy Than AUSTEDO XR in Head-to-Head Study
9个月前
Neurocrine's Phase 3 Valbenazine Trial for Dyskinetic Cerebral Palsy Fails to Meet Primary Endpoints
2个月前
Tardive Dyskinesia Market Projected to Reach USD 4.4 Billion by 2036, Growing at 8.1% CAGR Amid Pipeline Innovation
去年
Luye Pharma Launches Phase II Trial of LY03015 for Tardive Dyskinesia and Huntington's Disease
去年
AI-Discovered Drug SOM3355 Shows Promise in Treating Huntington's Disease
4个月前
IMPACT-TD Registry Reveals Stark Diagnostic Gap: Only 23% of Young Adults with Mood Disorders and Tardive Dyskinesia Symptoms Receive Formal Diagnosis
12个月前
Real-World Data Show AUSTEDO XR Delivers High Patient Satisfaction and Movement Improvement in Tardive Dyskinesia
第 1 页,共 606 页
上一页
下一页